These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9596204)

  • 1. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
    Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A
    Epilepsy Res; 1998 Nov; 32(3):371-8. PubMed ID: 9839777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing bioequivalence of generic modified-release antiepileptic drugs.
    Johnson EL; Chang YT; Davit B; Gidal BE; Krauss GL
    Neurology; 2016 Apr; 86(17):1597-604. PubMed ID: 27016518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):525-8. PubMed ID: 23611573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
    Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamazepine: a bioequivalence study and limited sampling modeling.
    Suarez-Kurtz G; Ribeiro FM; Salvadori MC; Struchiner CJ
    Int J Clin Pharmacol Ther; 2002 Sep; 40(9):424-30. PubMed ID: 12358160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
    Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
    JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ].
    Vojvodić NM; Sokić DV; Janković SM; Lević Z
    Srp Arh Celok Lek; 2002; 130(1-2):19-26. PubMed ID: 12073283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
    Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
    Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
    Mahmood I; Chamberlin N
    Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
    Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ
    Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
    Ahmad A; Garnett WR
    Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing bioequivalence of generic antiepilepsy drugs.
    Krauss GL; Caffo B; Chang YT; Hendrix CW; Chuang K
    Ann Neurol; 2011 Aug; 70(2):221-8. PubMed ID: 21717495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of carbamazepine from four different products and the occurrence of side effects.
    Olling M; Mensinga TT; Barends DM; Groen C; Lake OA; Meulenbelt J
    Biopharm Drug Dispos; 1999 Jan; 20(1):19-28. PubMed ID: 10086834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.
    Karalis V; Macheras P; Bialer M
    CNS Drugs; 2014 Jan; 28(1):69-77. PubMed ID: 24092569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.